EUCTR2019-003301-97-PL进行中（未招募）1 期
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 470
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Age >= 18 years
- •- Eastern Cooperative Oncology Group performance status of 0 or 1
- •- Histologically or cytologically confirmed ES-SCLC
- •- No prior systemic treatment for ES-SCLC
- •- Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors version 1.1
- •- Adequate hematologic and end-organ function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 250
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 220
排除标准
- •- Symptomatic or actively progressing CNS metastases
- •- Leptomeningeal disease
- •- Malignancies other than SCLC within 5 years prior to randomization,
- •with the exception of those with a negligible risk of metastasis or death
- •treated with expected curative outcome
- •- Active or history of autoimmune disease or immune deficiency
- •- History of idiopathic pulmonary fibrosis, organizing pneumonia, druginduced
- •pneumonitis, or idiopathic pneumonitis, or evidence of active
- •pneumonitis on screening chest CT scan
- •- Severe infection at the time of randomization
- •- Treatment with investigational agent within 28 days prior to initiation
- •of treatment study
- •- Current treatment with anti-viral therapy for HBV or HCV
- •- Prior treatment with CD137 agonists or immune checkpoint blockade
- •therapies, anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1
- •therapeutic antibodies
- •- Treatment with systemic immunostimulatory agents within 4 weeks or
- •5 drug elimination half-lives prior to randomization
- •- Treatment with systemic immunosuppressive medications within 1
- •week prior to randomization or anticipation of need for systemic
- •immunosuppressive medication during study treatment.
研究者
相似试验
进行中（未招募）
1 期
A Study of Atezolizumab with or without Tiragolumab (Anti-TIGIT Antibody) in Patients with Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma.Esophageal squamous cell carcinomaMedDRA version: 21.0Level: LLTClassification code 10055476Term: Esophageal squamous cell carcinomaSystem Organ Class: 100000004864EUCTR2020-001178-31-FRF. Hoffmann-La Roche Ltd750
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence.Early human epidermal growth factor receptor 2 (HER2) positive breast cancer.MedDRA version: 23.0Level: PTClassification code 10065430Term: HER2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003681-40-DEF. Hoffmann-La Roche Ltd1,700
进行中（未招募）
1 期
A Phase III study to assess whether etrolizumab is a safe and effective treatment for patients with moderately to severely active Crohn's diseaseCrohn`s DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2014-003824-36-NLF. Hoffmann-La Roche Ltd1,150
进行中（未招募）
1 期
A Study of Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate CancerMetastatic Castrate-Resistant Prostate CancerMedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 100000004864EUCTR2016-004429-17-PTF. Hoffmann-La Roche Ltd1,101
进行中（未招募）
1 期
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Generalized Myasthenia GravisGeneralized Myasthenia Gravis (gMG)MedDRA version: 21.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-004436-21-ESRoche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd240